Xenon Pharmaceuticals (XENE) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $34.33, +1.27% vs the prior close of $33.90.
- Volume 1.62M shares, 1.0x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
XENE rises 1.3% to $34.33. Closed at $34.33, +1.27% vs the prior close of $33.90. Day range $33.99–$34.99, opened at $34.11.
XENE daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — XENE rises 1.3% to $34.33
- Closed at $34.33, +1.27% vs the prior close of $33.90. Day range $33.99–$34.99, opened at $34.11.
- Volume was 1.62M shares, 1.0x its 50-day average of 1.62M.
- Price is -33.1% vs its 50-day average ($51.33) and -34.9% vs its 200-day average ($52.71).
- 52-week range $33.52–$72.66; today's close sits at 2% of that range, 52.8% below the 52-week high.
Oct 14, 2026 — XENE dips 1.5% to $33.90, a 52-week low, 3 down days in a row
- Closed at $33.90, -1.51% vs the prior close of $34.42. Day range $33.52–$34.84, opened at $34.12.
- Volume was 1.79M shares, 1.1x its 50-day average of 1.60M.
- Price is -34.7% vs its 50-day average ($51.93) and -35.7% vs its 200-day average ($52.76).
- 52-week range $33.52–$72.66; today's close sits at 1% of that range, 53.3% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — XENE slides 3.9% to $34.42, a 52-week low
- Closed at $34.42, -3.88% vs the prior close of $35.81. Day range $34.38–$35.90, opened at $35.65.
- Volume was 1.11M shares, 0.7x its 50-day average of 1.58M.
- Price is -34.5% vs its 50-day average ($52.53) and -34.8% vs its 200-day average ($52.82).
- 52-week range $34.38–$72.66; today's close sits at 0% of that range, 52.6% below the 52-week high.
Oct 12, 2026 — XENE dips 1.7% to $35.81, a 52-week low
- Closed at $35.81, -1.73% vs the prior close of $36.44. Day range $35.57–$36.54, opened at $36.45.
- Volume was 764.30K shares, 0.5x its 50-day average of 1.58M — lighter than usual.
- Price is -32.5% vs its 50-day average ($53.09) and -32.3% vs its 200-day average ($52.87).
- 52-week range $35.06–$72.66; today's close sits at 2% of that range, 50.7% below the 52-week high.
Oct 9, 2026 — XENE rises 0.8% to $36.44
- Closed at $36.44, +0.77% vs the prior close of $36.16. Day range $35.98–$36.70, opened at $36.05.
- Volume was 1.24M shares, 0.8x its 50-day average of 1.57M.
- Price is -32.0% vs its 50-day average ($53.62) and -31.1% vs its 200-day average ($52.91).
- 52-week range $35.06–$72.66; today's close sits at 4% of that range, 49.8% below the 52-week high.
Oct 8, 2026 — XENE dips 0.7% to $36.16, a 52-week low, 5 down days in a row
- Closed at $36.16, -0.69% vs the prior close of $36.41. Day range $35.06–$36.41, opened at $36.13.
- Volume was 2.27M shares, 1.5x its 50-day average of 1.54M.
- Price is -33.3% vs its 50-day average ($54.18) and -31.7% vs its 200-day average ($52.96).
- 52-week range $35.06–$72.66; today's close sits at 3% of that range, 50.2% below the 52-week high.
- That makes 5 straight losses.
Oct 7, 2026 — XENE dips 0.4% to $36.41, a 52-week low, 4 down days in a row
- Closed at $36.41, -0.44% vs the prior close of $36.57. Day range $35.78–$36.56, opened at $36.19.
- Volume was 1.97M shares, 1.3x its 50-day average of 1.51M.
- Price is -33.5% vs its 50-day average ($54.72) and -31.3% vs its 200-day average ($53.00).
- 52-week range $35.75–$72.66; today's close sits at 2% of that range, 49.9% below the 52-week high.
- That makes 4 straight losses.
Oct 6, 2026 — XENE dips 2.7% to $36.57 on 1.9x normal volume
- Closed at $36.57, -2.66% vs the prior close of $37.57. Day range $35.75–$37.79, opened at $37.78.
- Volume was 2.79M shares, 1.9x its 50-day average of 1.46M — unusually heavy trading.
- Price is -33.9% vs its 50-day average ($55.29) and -31.0% vs its 200-day average ($53.04).
- 52-week range $35.75–$72.66; today's close sits at 2% of that range, 49.7% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — XENE dips 1.2% to $37.57
- Closed at $37.57, -1.18% vs the prior close of $38.02. Day range $37.00–$38.22, opened at $38.02.
- Volume was 1.70M shares, 1.2x its 50-day average of 1.44M.
- Price is -32.8% vs its 50-day average ($55.87) and -29.2% vs its 200-day average ($53.07).
- 52-week range $36.07–$72.66; today's close sits at 4% of that range, 48.3% below the 52-week high.
Oct 2, 2026 — XENE dips 2.3% to $38.02
- Closed at $38.02, -2.34% vs the prior close of $38.93. Day range $37.26–$39.10, opened at $39.10.
- Volume was 1.94M shares, 1.4x its 50-day average of 1.41M.
- Price is -32.6% vs its 50-day average ($56.43) and -28.4% vs its 200-day average ($53.09).
- 52-week range $36.07–$72.66; today's close sits at 5% of that range, 47.7% below the 52-week high.
XENE latest news & SEC filings
Every SEC filing by or about XENE in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 1, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 1, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 3, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 31, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kenney Christopher John sold 6,368 shares at $60.17 (≈$383.16K) on Aug 28, 2026
- Kenney Christopher John sold 700 shares at $60.98 (≈$42.69K) on Aug 28, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 28, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 13, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Gannon Steven sold 10,000 shares at $64.06 (≈$640.60K) on Aug 11, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 13, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$110.74M (prior year -$84.71M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$1.11 (prior year -$1.07) (loss widened vs Jun 30, 2025)
Aug 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade XENE
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 3, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.49% (largest 30.7%). That is a volatile stock.
- Liquidity: about 3.08M shares (≈$105.81M) trade per day on average.
- 52-week position: $34.33 vs a range of $33.52–$72.66 (2% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Christopher John Kenney sold 6,368 shares on Aug 28, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jun 3, 2026.
- Share count: 96.84M shares outstanding (Aug 3, 2026), +25.6% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
XENE market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 34.11 | 34.99 | 33.99 | 34.33 | 1.62M |
| Oct 14, 2026 | 34.12 | 34.84 | 33.52 | 33.90 | 1.79M |
| Oct 13, 2026 | 35.65 | 35.90 | 34.38 | 34.42 | 1.11M |
| Oct 12, 2026 | 36.45 | 36.54 | 35.57 | 35.81 | 764.30K |
| Oct 9, 2026 | 36.05 | 36.70 | 35.98 | 36.44 | 1.24M |
| Oct 8, 2026 | 36.13 | 36.41 | 35.06 | 36.16 | 2.27M |
| Oct 7, 2026 | 36.19 | 36.56 | 35.78 | 36.41 | 1.97M |
| Oct 6, 2026 | 37.78 | 37.79 | 35.75 | 36.57 | 2.79M |
| Oct 5, 2026 | 38.02 | 38.22 | 37.00 | 37.57 | 1.70M |
| Oct 2, 2026 | 39.10 | 39.10 | 37.26 | 38.02 | 1.94M |
| Oct 1, 2026 | 38.31 | 39.92 | 38.08 | 38.93 | 3.66M |
| Sep 30, 2026 | 37.38 | 37.53 | 36.71 | 37.19 | 2.47M |
| Sep 29, 2026 | 36.30 | 37.43 | 36.20 | 37.25 | 2.75M |
| Sep 28, 2026 | 36.85 | 36.85 | 36.10 | 36.72 | 2.52M |
| Sep 25, 2026 | 38.10 | 38.26 | 36.48 | 36.94 | 2.43M |
| Sep 24, 2026 | 36.50 | 38.34 | 36.07 | 38.06 | 3.11M |
| Sep 23, 2026 | 39.51 | 39.51 | 36.07 | 36.56 | 3.17M |
| Sep 22, 2026 | 39.76 | 39.76 | 37.97 | 39.09 | 2.35M |
| Sep 21, 2026 | 40.00 | 40.26 | 38.60 | 38.99 | 4.05M |
| Sep 18, 2026 | 44.02 | 44.85 | 39.08 | 39.75 | 17.95M |
About Xenon Pharmaceuticals
Xenon Pharmaceuticals (XENE) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in BURNABY. State of incorporation: British Columbia, Canada. Fiscal year ends December 31. SEC CIK 1582313.
XENE board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Gillian Cannon | Director | Jun 8, 2026 |
| Steven Gannon | Director | Aug 13, 2026 |
| Elizabeth A. Garofalo | Director | Jun 3, 2026 |
| Justin D. Gover | Director | Jun 3, 2026 |
| Ian Mortimer | PRESIDENT & CEO | Mar 13, 2026 |
| Patrick Machado | Director | Jun 3, 2026 |
| Gary Patou | Director | Jun 8, 2026 |
| Dawn Svoronos | Director | Sep 3, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Darren S Cline | Chief Commercial Officer | Jan 9, 2026 |
| Andrea Difabio | Chief Legal Officer | Mar 13, 2026 |
| Christopher John Kenney | Chief Medical Officer | Aug 31, 2026 |
| Thomas Patrick Kelly | Chief Financial Officer | Oct 17, 2025 |
| Ian Mortimer | PRESIDENT & CEO | Mar 13, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 28, 2026 | Christopher John Kenney | Sale | 6,368 | $60.17 |
| Aug 28, 2026 | Christopher John Kenney | Sale | 700 | $60.98 |
| Aug 11, 2026 | Steven Gannon | Sale | 10,000 | $64.06 |
| Jun 5, 2026 | Gillian Cannon | Sale | 1,190 | $53.14 |
| Jun 5, 2026 | Gary Patou | Sale | 1,322 | $53.14 |
| Mar 13, 2026 | Andrea Difabio | Sale | 1,342 | $55.23 |
| Mar 13, 2026 | Ian Mortimer | Sale | 7,308 | $55.23 |
| Mar 13, 2026 | Christopher John Kenney | Sale | 1,410 | $55.23 |
| Mar 10, 2026 | Ian Mortimer | Sale | 11,269 | $60.11 |
| Mar 10, 2026 | Andrea Difabio | Sale | 2,607 | $60.11 |
| Mar 10, 2026 | Christopher John Kenney | Sale | 2,771 | $60.11 |
| Mar 9, 2026 | Ian Mortimer | Sale | 21,791 | $58.81 |
| Mar 9, 2026 | Ian Mortimer | Sale | 31,694 | $59.88 |
| Mar 9, 2026 | Ian Mortimer | Sale | 21,515 | $60.49 |
| Mar 9, 2026 | Ian Mortimer | Sale | 12,479 | $59.50 |
XENE financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-345.91M | -4.36 | $-279.12M |
| Dec 31, 2024 | — | $-234.33M | -3.01 | $-181.39M |
| Dec 31, 2023 | — | $-182.39M | -2.73 | $-151.11M |
| Dec 31, 2022 | — | $-125.37M | -2.06 | $-101.03M |
| Dec 31, 2021 | — | $-78.88M | -1.77 | $-69.50M |
Latest balance sheet: total assets $1.30B, total liabilities $53.38M, cash $119.53M (as of Jun 30, 2026).
XENE earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $64.55 |
| May 7, 2026 | 8-K Item 2.02 (results) | $56.00 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $44.92 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $41.12 |
| Aug 11, 2025 | 8-K Item 2.02 (results) | $34.11 |
| May 12, 2025 | 8-K Item 2.02 (results) | $35.85 |
| Feb 27, 2025 | 8-K Item 2.02 (results) | $38.31 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $43.39 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
| Feb 29, 2024 | 8-K Item 2.02 (results) | — |
| Nov 8, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on XENE
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.